ANDA 87717, held by Barr Labs. Dipyridamole.
As of Nov 16, 2026, ANDA 87717 (Dipyridamole), held by Barr Labs, was first approved by FDA on Oct 3, 1990, with 20 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 3, 1990 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dipyridamole75MG ยท tablet;oral | Dipyridamole | Rx |
| Aug 18, 2006 | Supplement 39Labeling | Approved | None posted |
| Oct 5, 2005 | Supplement 35Labeling | Approved | None posted |
| Mar 7, 2001 | Supplement 33Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 32Manufacturing | Approved | None posted |
| Dec 21, 1999 | Supplement 31Manufacturing | Approved | None posted |
| May 20, 1999 | Supplement 30Manufacturing | Approved | None posted |
| Dec 1, 1998 | Supplement 29Manufacturing | Approved | None posted |
| Mar 30, 1998 | Supplement 28Manufacturing | Approved | None posted |
| Aug 13, 1996 | Supplement 26Manufacturing | Approved | None posted |
| Apr 17, 1996 | Supplement 27Manufacturing | Approved | None posted |
| Aug 13, 1992 | Supplement 22Labeling | Approved | None posted |
| Apr 3, 1992 | Supplement 21Manufacturing | Approved | None posted |
| Apr 3, 1992 | Supplement 19Manufacturing | Approved | None posted |
| Aug 30, 1991 | Supplement 18Manufacturing | Approved | None posted |
| Oct 3, 1990 | Supplement 12Labeling | Approved | None posted |
| Oct 3, 1990 | Original application | Approved | None posted |
| Mar 15, 1990 | Supplement 17Bioequivalence | Approved | None posted |
| Oct 7, 1987 | Supplement 16Manufacturing | Approved | None posted |
| Sep 15, 1987 | Supplement 15Manufacturing | Approved | None posted |
| Sep 15, 1987 | Supplement 14Manufacturing | Approved | None posted |
| Mar 25, 1987 | Supplement 11Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters